RNAIII-inhibiting peptide(TFA) | Cytiva思拓凡-Whatman滤纸滤膜滤器

RNAIII-inhibiting peptide(TFA); 纯度: 99.75%

RNAIII-inhibiting peptide(TFA) 是一种有效的 Staphylococcus aureus 多肽抑制剂，在蜂窝组织炎、角膜炎、化脓性关节炎、骨肌炎和乳腺炎等疾病中有功效。

RNAIII-inhibiting peptide(TFA) Chemical Structure

规格	价格	是否有货	数量
1 mg	￥2100	In-stock
5 mg	￥6300	In-stock
10 mg	;	询价	;
50 mg	;	询价	;

* Please select Quantity before adding items.

RNAIII-inhibiting peptide(TFA) 相关产品

bull;相关化合物库:

Bioactive Compound Library Plus
Peptide Library

生物活性

RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus, effective in the diseases such as cellulitis, keratitis, septic arthritis, osteomylitis and mastitis.

IC₅₀ Target

Staphylococcus aureus^[1]

体外研究
(In Vitro)

RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus. RNAIII-inhibiting peptide (RIP) inhibits the synthesis of both RNAII and RNAIII, while RAP activates in wild type S. aureus cells. RNAIII-inhibiting peptide (5 μg/10⁶ cells) potently reduces bacterial cell adhesion to HEp2 cells in the absence of serum, but with slight overall reduction the presence of serum. RNAIII-inhibiting peptide inhibits while RAP induces the phosphorylation of TRAP^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

RNAIII-inhibiting peptide (20 mg/kg, i.v.) decreases lethality in mice challenged with S. aureus ATCC 25923, with the lethality rate of 70%, and when combined with cefazolin, imipenem, vancomycin, the rates are 20%, 15% and 10%. RNAIII-inhibiting peptide (20 mg/kg, i.v.) also causes decreased lethality in mice challenged with S. aureus Smith, with the lethality rate of 75%, and the lethality rate decreases to 30%, 10% and 10% when combined with cefazolin, imipenem, vancomycin^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

1027.01

Formula

C₄₇H₅₇F₃N₁₀O₁₃

Sequence

Tyr-Ser-Pro-Trp-Thr-Asn-Phe

Sequence Shortening

YSPWTNF

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder	-80deg;C	2 years
	-20deg;C	1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (sealed storage, away from moisture)

溶解性数据

In Vitro:;

DMSO : ≥ 150 mg/mL (146.06 mM)

* “≥” means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.9737 mL	4.8685 mL	9.7370 mL
5 mM	0.1947 mL	0.9737 mL	1.9474 mL
10 mM	0.0974 mL	0.4869 mL	0.9737 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

参考文献

[1]. Gov Y, et al. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis. Peptides. 2001 Oct;22(10):1609-20.

[2]. Giacometti A, et al. RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis. Peptides. 2005 Feb;26(2):169-75.

Animal Administration ^[2]	Mice^[2] Mice are randomized to receive intravenously isotonic sodium chloride solution (controls C1 and C2) and 20 mg/kg RNAIII-inhibiting peptide alone or combined with 20 mg/kg cefazolin, 10 mg/kg imipenem, or 10 mg/kg vancomycin. Animals are returned to individual cages and monitored for 7 days. The endpoints of the study are quantitative plasma bacterial evaluation and lethality. For each animal model, toxicity is evaluated on the basis of the presence of any drug-related adverse effects, i.e. local signs of inflammation, anorexia, weight loss, vomiting, diarrhea, fever, and behavioral alterations. In particular, to evaluate the physiological effects of RNAIII-inhibiting peptide, temperature, pulse, blood pressure, respirations and oxygenation are monitored in a supplementary RNAIII-inhibiting peptide-treated group without infection^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Gov Y, et al. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis. Peptides. 2001 Oct;22(10):1609-20. [2]. Giacometti A, et al. RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis. Peptides. 2005 Feb;26(2):169-75.

Animal Administration
^[2]

Mice^[2]
Mice are randomized to receive intravenously isotonic sodium chloride solution (controls C1 and C2) and 20 mg/kg RNAIII-inhibiting peptide alone or combined with 20 mg/kg cefazolin, 10 mg/kg imipenem, or 10 mg/kg vancomycin. Animals are returned to individual cages and monitored for 7 days. The endpoints of the study are quantitative plasma bacterial evaluation and lethality. For each animal model, toxicity is evaluated on the basis of the presence of any drug-related adverse effects, i.e. local signs of inflammation, anorexia, weight loss, vomiting, diarrhea, fever, and behavioral alterations. In particular, to evaluate the physiological effects of RNAIII-inhibiting peptide, temperature, pulse, blood pressure, respirations and oxygenation are monitored in a supplementary RNAIII-inhibiting peptide-treated group without infection^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Gov Y, et al. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis. Peptides. 2001 Oct;22(10):1609-20.

[2]. Giacometti A, et al. RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis. Peptides. 2005 Feb;26(2):169-75.